Perimenopause Vaginal Dryness

By Sophora Health Editorial Team · Medically reviewed · Published July 2026 · Last reviewed July 2026

It started as a dryness you noticed but did not think much of. Then sex became uncomfortable in a way it never used to be. Then it became something you started avoiding. Not because you did not want intimacy, but because you knew what came after: soreness, sometimes a raw, burning feeling that lingered for a day or two. You may have also noticed you are needing the bathroom more, or getting more urinary tract infections than you used to. These are not separate problems. They are one condition, and it has a name most women have never been told.

The condition is genitourinary syndrome of menopause, or GSM. It affects up to 87 percent of postmenopausal women and begins for many during perimenopause. Unlike hot flashes, which tend to improve over time, GSM is progressive without treatment. It is also one of the most effectively treatable perimenopause symptoms, and one of the most under-treated. Only 4 to 35 percent of affected women use any treatment for it.

Someone important to you needs this too.

WhatsApp iMessage Copy Link Email

What is actually happening: genitourinary syndrome of menopause

Estrogen maintains the thickness, elasticity, moisture, and blood supply of the vaginal, vulvar, and urinary tissues. These tissues have among the highest concentrations of estrogen receptors in the body, which is why they respond so directly and so early to hormonal change. As estrogen declines through perimenopause, the vaginal walls become thinner, less elastic, and less able to produce their own natural lubrication. Blood flow to the area decreases. The vaginal pH rises, which changes the local microbiome and increases susceptibility to infection.

This collection of changes was renamed genitourinary syndrome of menopause in 2014. The older term vaginal atrophy was replaced because symptoms extend beyond the vagina into the vulva and urinary tract. Hot flashes and night sweats are driven by fluctuating estrogen and tend to improve once levels settle. GSM is different: driven by sustained low estrogen, it is progressive without treatment. It does not resolve on its own the way many perimenopause symptoms eventually do.

The full symptom picture of GSM

Vaginal: dryness, burning, itching, irritation, thinning tissue
Sexual: pain with intercourse, reduced lubrication, reduced arousal, discomfort that can last after sex ends
Urinary: urgency, increased frequency, burning with urination, recurrent urinary tract infections, in some cases stress incontinence

Many women experience only the vaginal symptoms and never connect the recurrent UTIs or urinary urgency to the same hormonal cause. The three symptom groups share one underlying mechanism, which is why they so often improve together with the right treatment.

Someone important to you needs this too.

WhatsApp iMessage Copy Link Email

What actually helps

Vaginal moisturisers, used regularly

Vaginal moisturisers are different from lubricants. They are usually used two or three times a week, whether or not you are sexually active. They help keep vaginal tissue hydrated and may improve dryness and discomfort over time. They are available over the counter and can be a useful first step.

Lubricants for intercourse

Lubricants are used during intercourse to reduce friction and discomfort. Unlike moisturisers, they provide temporary relief rather than treating ongoing vaginal dryness. Water-based or silicone-based lubricants without added fragrance, flavouring, or warming ingredients are often better tolerated by sensitive tissue.

Local vaginal estrogen

Low-dose vaginal estrogen is one of the most effective treatments for genitourinary syndrome of menopause (GSM). It is available as a cream, tablet, insert, or ring placed directly in the vagina. It can improve vaginal dryness, pain during intercourse, urinary symptoms, and recurrent urinary tract infections.

Because vaginal estrogen works mainly where it is applied, very little is absorbed into the bloodstream. This means its risk profile is different from systemic hormone therapy, such as estrogen pills or patches.

In July 2025, an FDA advisory panel recommended removing the broad boxed warning from vaginal estrogen products because the warning was largely based on evidence from systemic hormone therapy rather than low-dose vaginal estrogen. For some women with a history of breast cancer, vaginal estrogen may also be considered after discussion with their healthcare and oncology teams.

Vaginal DHEA and other options

Vaginal DHEA, also known as prasterone, is another prescription option for vaginal symptoms and pain during intercourse. Ospemifene is an oral prescription medicine that can also help with painful intercourse related to menopause. A healthcare professional can help you decide which treatment best suits your symptoms and medical history.

Sexual activity and pelvic floor health

Regular sexual activity, with a partner or alone, may help maintain blood flow and flexibility in vaginal tissue. However, it is not a replacement for treatment when symptoms are significant.

If pelvic floor problems are contributing to painful intercourse or urinary symptoms, a pelvic floor physiotherapist may also be able to help.

“This is one of the most treatable symptoms of the entire menopausal transition, and one of the least discussed. That gap between how fixable it is and how rarely it gets addressed is the real problem.”

When to see a doctor

Raise this with a doctor if:

Vaginal dryness or discomfort is affecting your daily life or intimacy
Over-the-counter moisturisers have not provided sufficient relief
You have recurrent urinary tract infections
You have bleeding after sex, which needs assessment to rule out other causes
You want to discuss local vaginal estrogen, DHEA, or other prescription options
You have a history of breast or other hormone-sensitive cancer and want to understand your options specifically

Use Sophora’s The Answers You Need, which builds a doctor-ready summary from four questions, before your appointment. GSM is consistently under-discussed in medical consultations, partly because patients are reluctant to raise it and partly because it is not always asked about proactively. Having the specific language ready, including naming genitourinary syndrome of menopause directly, changes the conversation from a vague mention to a specific, treatable request.

Questions you are probably asking

Is vaginal dryness a normal part of perimenopause?

Yes, extremely common, affecting up to 87 percent of postmenopausal women and beginning for many during perimenopause. Common does not mean untreatable or something to simply live with. GSM has multiple effective treatments. Unlike some perimenopause symptoms that improve on their own, GSM tends to worsen without treatment, which makes addressing it early worthwhile.

Is vaginal estrogen safe?

The evidence strongly supports its safety. The 2025 FDA panel recommended removing the black box warning, which was based on systemic hormone data that does not apply to local vaginal use. Vaginal estrogen acts locally with minimal absorption into the bloodstream. It is considered appropriate for many women, including some breast cancer survivors, following a conversation with their treating oncology team about their individual situation.

Why am I getting more urinary tract infections since perimenopause started?

This is a recognised part of GSM. Declining estrogen changes the vaginal and urinary tract tissue and raises vaginal pH, which alters the local microbiome in ways that make urinary tract infections more likely. Local vaginal estrogen has strong evidence for reducing recurrent UTIs specifically, in addition to treating vaginal dryness, which is why the same treatment often addresses both problems simultaneously.

How long does it take for treatment to work?

With local vaginal estrogen, meaningful symptom relief and UTI reduction can take up to twelve weeks of consistent use, though many women notice some improvement earlier. A mild burning sensation or breast tenderness in the first few weeks is common and usually settles. Vaginal moisturisers used consistently over several weeks also produce a gradual improvement rather than immediate relief. Consistency matters more than any single application.

Why does this feel harder to talk about than other perimenopause symptoms?

Vaginal and sexual symptoms carry a different kind of privacy than hot flashes or sleep problems. Many women find them harder to raise even with a trusted doctor. This reluctance is common and understandable, but it is also the main barrier standing between a highly treatable condition and the relief that treatment provides. Naming the specific medical term, genitourinary syndrome of menopause, can make the conversation feel less personal and more clinical, which some women find easier. Doctors who work regularly in menopause care are used to this conversation and will not be surprised by it.

In summary

You now know: Vaginal dryness is part of genitourinary syndrome of menopause (GSM). Declining estrogen thins the vaginal, vulvar, and urinary tissues and reduces their blood supply. It affects up to 87 percent of postmenopausal women and, unlike hot flashes, tends to worsen without treatment.

One thing to do: Start a regular vaginal moisturiser, used two to three times weekly regardless of sexual activity, as a genuinely effective first step. If symptoms persist, raise local vaginal estrogen with a doctor. The safety evidence and FDA guidance are clearer now than in over two decades.

Hold onto this: This is one of the most effectively treatable symptoms of the entire transition. The gap is not in the medicine. It is in the conversation. Naming it clearly is most of what stands between where you are and meaningful relief.